news
China’s Sinopharm reports strong interim results for its Covid-19 vaccine Simone McCarthy and Zhuang Pinghui Developers of the Sinopharm vaccine say an interim analysis has found it to be nearly 80 per cent effective against Covid-19. Photo: EPA-EFE
A vaccine developed by China National Pharmaceutical Group (Sinopharm) has been found to be 79.34 per cent effective against Covid-19, according to an interim analysis, the company said.
The vaccine was shown to be safe, and participants receiving the two-dose course produced a high level of antibodies against the virus at a rate of 99.52 per cent, according to a statement posted on Wednesday by the company s subsidiary Beijing Institute of Biological Products - which has also formally submitted an application to China s regulators for conditional listing, it said.
Channels Television
Updated December 30, 2020
A medical worker waits for the next individual to take a swab test for the COVID-19 coronavirus at a hospital in Beijing in December 30, 2020. Noel Celis / AFP
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
China has been racing against the West to develop its own Covid-19 vaccines, with five already in large-scale Phase 3 clinical trials.
But Wednesday’s announced was the first data released regarding the efficacy of a Chinese vaccine candidate.
Views: Visits 17
(FILES) In this file photo taken on December 9, 2020, a health worker prepares a syringe to inoculate a volunteer with a COVID-19 vaccine produced by China’s Sinopharm during its trial at the Clinical Studies Center of the Cayetano Heredia University in Lima. – Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said on December 30, 2020, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia. (Photo by ERNESTO BENAVIDES / AFP)
Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79 percent effective, the Chinese pharma giant said Wednesday, lower than rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.